p53-specific CD8+T-cell responses in individuals with cutaneous squamous cell carcinoma

被引:14
作者
Black, AP
Bailey, A
Jones, L
Turner, RJ
Hollowood, K
Ogg, GS [1 ]
机构
[1] John Radcliffe Hosp, Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford OX3 9DU, England
[2] Churchill Hosp, Dept Dermatol, Oxford OX3 7LJ, England
[3] John Radcliffe Hosp, Dept Pathol, Oxford OX3 9DU, England
基金
英国医学研究理事会;
关键词
p53; squamous cell carcinoma; T cells;
D O I
10.1111/j.1365-2133.2005.06878.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Systemic immunosuppression is a significant risk factor for cutaneous squamous cell carcinoma (SCC). p53 is mutated and overexpressed in up to 90% of cutaneous SCC lesions. Despite considerable evidence that the immune response is important in the control of cutaneous SCC, there are no studies documenting potential tumour-associated antigens. Objectives We tested the hypothesis that individuals with cutaneous SCC have functional circulating CD8+ T cells specific for p53. Methods Interferon-gamma immunosorbent assays were used to screen peripheral blood mononuclear cells for reactivity to six p53-derived HLA-A*0201-restricted epitopes from HLA-A*0201-positive patients and controls. Results We observed significantly elevated frequencies of p53-specific CD8+ T cells in seven of 26 individuals with cutaneous SCC and in one of 10 controls. The degree of lymphocytic infiltrate significantly correlated with the frequency of CD8+ T cells specific for p53 epitopes, but not with control epitopes. Conclusions Overall, these data suggest that p53 may represent a target for CD8+ T cells in a proportion of individuals with cutaneous SCC.
引用
收藏
页码:987 / 991
页数:5
相关论文
共 29 条
[1]  
Barfoed AM, 2000, SCAND J IMMUNOL, V51, P128
[2]   Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides [J].
Bertholet, S ;
Iggo, R ;
Corradin, G .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (03) :798-801
[3]   The role of p53 in the immunobiology of cutaneous squamous cell carcinoma [J].
Black, APB ;
Ogg, GS .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2003, 132 (03) :379-384
[4]  
Chikamatsu K, 1999, CLIN CANCER RES, V5, P1281
[5]   ACCUMULATION OF P53 IN A MUTANT-CELL LINE DEFECTIVE IN THE UBIQUITIN PATHWAY [J].
CHOWDARY, DR ;
DERMODY, JJ ;
JHA, KK ;
OZER, HL .
MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (03) :1997-2003
[6]  
Eura M, 2000, CLIN CANCER RES, V6, P979
[7]   Identification of p53 peptides recognized by CD8+ T lymphocytes from patients with bladder cancer [J].
Ferriès, E ;
Connan, F ;
Pagès, F ;
Gaston, J ;
Hagnéré, AM ;
Vieillefond, A ;
Thiounn, N ;
Guillet, JG ;
Choppin, J .
HUMAN IMMUNOLOGY, 2001, 62 (08) :791-798
[8]   MAPPING AND RANKING OF POTENTIAL CYTOTOXIC T-EPITOPES IN THE P53 PROTEIN - EFFECT OF MUTATIONS AND POLYMORPHISM ON PEPTIDE BINDING TO PURIFIED AND REFOLDED HLA MOLECULES [J].
GNJATIC, S ;
DEPAILLERETS, BB ;
GUILLET, JG ;
CHOPPIN, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (06) :1638-1642
[9]  
Gnjatic S, 1998, J IMMUNOL, V160, P328
[10]   SPONTANEOUS REGRESSION OF HUMAN-MELANOMA NONMELANOMA SKIN-CANCER - ASSOCIATION WITH INFILTRATING CD4(+) T-CELLS [J].
HALLIDAY, GM ;
PATEL, A ;
HUNT, MJ ;
TEFANY, FJ ;
BARNETSON, RSC .
WORLD JOURNAL OF SURGERY, 1995, 19 (03) :352-358